Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
IO Biotech Inc (IOBT)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -58.56% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 1.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.85M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 258891 | Beta 0.42 | 52 Weeks Range 0.66 - 1.95 | Updated Date 01/14/2025 |
52 Weeks Range 0.66 - 1.95 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.98% | Return on Equity (TTM) -87.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -21317360 | Price to Sales(TTM) - |
Enterprise Value -21317360 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.36 | Shares Outstanding 65880900 | Shares Floating 27841933 |
Shares Outstanding 65880900 | Shares Floating 27841933 | ||
Percent Insiders 0.24 | Percent Institutions 76.79 |
AI Summary
IO Biotech Inc.: A Comprehensive Overview
Company Profile:
History and Background: IO Biotech Inc. (IOBT), formerly known as Agensys, Inc., was founded in 1998 and is headquartered in San Diego, California. The company focuses on the discovery and development of novel cancer immunotherapy products. Its lead product candidate, IO102-IO103, is a proprietary bispecific antibody designed to target and activate the immune system to fight EGFR-expressing tumors.
Core Business Areas: IOBT's core business areas include:
- Discovery and development of next-generation cancer immunotherapies
- Clinical research and development of IO102-IO103
- Collaboration with leading research institutions and pharmaceutical companies
Leadership Team and Corporate Structure:
- Dr. Gary Johnson, President and Chief Executive Officer
- Dr. John F. DiPersio, Chief Medical Officer
- Dr. Robert Li, Chief Scientific Officer
- Ms. Kathy Galvez, Chief Financial Officer
- The Board of Directors consists of experienced professionals with expertise in biotechnology, medicine, and finance.
Top Products and Market Share:
Top Products:
- IO102-IO103: A bispecific antibody targeting EGFR-expressing tumors, currently in Phase 2 clinical trials.
Market Share:
- IO102-IO103 is not yet approved for commercial use, so it does not currently hold any market share.
- The global market for cancer immunotherapy is expected to reach $130.8 billion by 2025, with EGFR-targeted therapies representing a significant segment.
- IOBT faces competition from established players like Bristol-Myers Squibb (BMY), Merck (MRK), and Roche (RHHBY) in the EGFR-targeted therapy market.
Total Addressable Market:
The total addressable market (TAM) for IO102-IO103 is estimated to be approximately 500,000 patients with EGFR-expressing tumors globally.
Financial Performance:
Recent Financial Performance:
- IOBT is a clinical-stage company with no product currently approved for commercial use.
- Revenue for 2022 was $4.2 million, primarily from collaboration agreements and research grants.
- The company reported a net loss of $48.5 million in 2022.
Financial Health:
- IOBT has a strong cash position of $213.4 million as of December 31, 2022.
- The company is currently funded through its cash reserves and collaborations.
Dividends and Shareholder Returns:
- IOBT does not currently pay dividends as it is focused on reinvesting profits into research and development.
- Shareholder returns have been negative in recent years due to the company's early-stage development and lack of product revenue.
Growth Trajectory:
Historical Growth:
- IOBT has made significant progress in advancing its lead product candidate, IO102-IO103, into Phase 2 clinical trials.
- The company has also expanded its intellectual property portfolio through patents and collaborations.
Future Growth:
- IOBT's growth prospects are contingent on the success of its clinical trials and regulatory approvals.
- The company is also exploring opportunities to expand its pipeline and enter new markets.
Market Dynamics:
Industry Overview:
- The cancer immunotherapy market is rapidly growing due to advancements in research and technology.
- Key trends include the development of personalized therapies, combination therapies, and early-stage cancer detection.
Competitive Landscape:
- IOBT faces competition from established pharmaceutical companies and emerging biotechnology startups.
- The company differentiates itself through its proprietary bispecific antibody platform and its focus on EGFR-expressing tumors.
Competitors:
- Bristol-Myers Squibb (BMY)
- Merck (MRK)
- Roche (RHHBY)
- Amgen (AMGN)
- Pfizer (PFE)
Competitive Advantages:
- Proprietary bispecific antibody platform
- Focus on EGFR-expressing tumors
- Experienced management team
- Strong cash position
Challenges and Opportunities:
Challenges:
- Clinical trial risk
- Regulatory approvals
- Competition from established players
Opportunities:
- Growing cancer immunotherapy market
- Unmet medical need in EGFR-expressing tumors
- Potential for strategic partnerships
Recent Acquisitions (last 3 years):
- IOBT has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on an analysis of various factors, including financial health, market position, and future prospects, IOBT receives an AI-based fundamental rating of 6.5 out of 10.
Sources and Disclaimers:
- Financial data from IOBT's annual reports and filings with the U.S. Securities and Exchange Commission (SEC)
- Market data from industry reports and analysis
Disclaimer: This information is intended for educational purposes only and should not be considered investment advice.
Conclusion:
IO Biotech Inc. is a clinical-stage biotechnology company with a promising pipeline of cancer immunotherapy products. The company's lead candidate, IO102-IO103, has the potential to address a significant unmet medical need in EGFR-expressing tumors. However, IOBT faces competition from established players and its future success depends on the outcome of its clinical trials and regulatory approvals.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.iobiotech.com |
Full time employees 74 | Website https://www.iobiotech.com |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.